Sosei to regain rights to IBD drug after GSK discontinues programme
Pharmaceutical Technology
NOVEMBER 24, 2023
The Sosei Heptares oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.
Clinical Development Drugs Licensing 
BREAKING: Breast cancer drug licensed as preventative measure
Outsourcing Pharma
NOVEMBER 7, 2023
A breast cancer drug that has been used for many years to treat the disease, has been licensed today (November 7) as a preventative measure.
Licensing 
110
110 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AstraZeneca licenses CSPC’s cardiovascular drug in $2 billion deal
Outsourcing Pharma
OCTOBER 10, 2024
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Licensing 109
109 
Innovating Immune-Modulating Therapies in Autoimmune Disorders ft. Dr. Mario Marcondes, VP Head of Clinical Development, Nektar Therapeutics
XTalks
FEBRUARY 5, 2025
In this episode, Ayesha spoke with Mario Marcondes, MD, PhD, VP Head of Clinical Development at Nektar Therapeutics , a company focused on the discovery and development of novel therapies for autoimmune disorders and cancer. Dr. Marcondes is a licensed and trained physician, specializing in oncology and immune oncology.
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”
Antibody 130
130 
Roche licenses drug to target cancer DNA damage response
Outsourcing Pharma
JULY 18, 2023
Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.
DNA 85
85 
Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug
BioSpace
NOVEMBER 10, 2021
Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.
Licensing 78
78 
ImmunoForge expands agreement with Duke University for drug development
Pharmaceutical Technology
MAY 19, 2023
ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.
Development 130
130 
EC grants approval for BioMarin’s gene therapy to treat Hemophilia A
Pharmaceutical Technology
AUGUST 25, 2022
The approval is based on comprehensive data from the clinical development programme of Roctavian, including two-year findings from the international Phase III GENEr8-1 clinical trial. The company plans to resubmit a Biologics License Application (BLA) for Roctavian by the end of next month.
Gene Therapy 264
264 
Astellas to support development of Taysha’s gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Additionally, Astellas will obtain an exclusive option for licencing two clinical-stage programmes of Taysha, namely TSHA-102 and TSHA-120, for Rett syndrome and GAN, respectively. Astellas will also receive specific rights linked to any possible change of Taysha’s control.
Gene Therapy 264
264 
How patient-on-a-chip tech could be the future of drug discovery
pharmaphorum
MAY 4, 2022
Testing drug compounds on a chip designed to mimic human organs sounds closer to science fiction than reality, yet the technology already exists and is already being put to use. The limits of animal models in drug discovery are well known. Quris has taken its technology and used it to develop its own drug candidate pipeline.
Drugs 143
143 
Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate
XTalks
MARCH 17, 2025
Roche, a global leader in biotechnology and diagnostics, has entered into an exclusive collaboration and licensing agreement with Zealand Pharma, a specialist in innovative therapeutics, to co-develop and co-commercialize petrelintide as a potential foundational therapy for people with overweight and obesity. billion $1.4
Hormones 59
59 
Exelixis licenses AI-designed cancer drug from Insilico Medicine
Outsourcing Pharma
SEPTEMBER 14, 2023
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.
Medicine 93
93 
Preclinical program with potential for disease modifying therapeutic
Outsourcing Pharma
JANUARY 13, 2023
A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.
physIQ licenses virtual trial tech to Janssen in multi-year deal
pharmaphorum
APRIL 22, 2021
Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors.
Licensing 72
72 
Stalicla signs licence deal for Evgen Pharma’s lead asset SFX-01
Pharmaceutical Technology
OCTOBER 11, 2022
Swiss biotech company Stalicla has signed a licensing deal with Evgen Pharma for the latter’s lead asset, SFX-01, in neurodevelopmental disorders and schizophrenia. in milestone payments that include $5m upon receipt of the investigational new drug (IND) from the US Food and Drug Administration (FDA), which is expected late next year.
Redx shares soar after IPF drug licence deal with AstraZeneca
pharmaphorum
AUGUST 4, 2020
Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to AstraZeneca. AstraZeneca has bought an exclusive global licence to develop and market RXC006, a porcupine inhibitor for fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Drugs 109
109 
Pfizer acquires ADC pioneer Seagen for $43bn
Pharmaceutical Technology
MARCH 23, 2023
Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.
Licensing 147
147 
Danicamtiv, what is the likelihood that the drug will be approved?
Pharmaceutical Technology
JANUARY 2, 2023
Danicamtiv is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. It is developed based on MyoKardia's drug discovery platform. It is a new molecular entity which is administered through oral route as a suspension and tablet.
Drugs 100
100 
AbbVie begins trials of COVID-19 antibody therapy
pharmaphorum
DECEMBER 16, 2020
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.
Antibody 98
98 
Bayer adds menopause drug to pipeline with KaNDy acquisition
pharmaphorum
AUGUST 11, 2020
Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline. At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats.
Drugs 98
98 
Why Proactive AME Studies are Critical to Accelerating Your Approval Journey
Worldwide Clinical Trials
FEBRUARY 21, 2024
During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study. At Worldwide, our early phase team has conducted these studies for over 20 years, gaining invaluable experience and insights into best practices for an AME study.
Clinical Trials 200
200 
Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug
pharmaphorum
NOVEMBER 10, 2021
Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 The drug was the first in the oral CGRP inhibitor class to get an prevention indication approved by the FDA in May, and that has helped accelerate its rollout, bringing in $336 million in US sales for Biohaven so far this year.
Licensing 52
52 
EVOQ Therapeutics Announces a License And Collaboration Agreement with Amgen
The Pharma Data
JANUARY 12, 2021
13, 2021 /PRNewswire/ — EVOQ Therapeutics today announced a license and collaboration agreement with Amgen for the discovery and development of novel drugs for autoimmune disorders. EVOQ Therapeutics today announced a license and collaboration agreement with Amgen. ANN ARBOR, Mich. , www.evoqtherapeutics.com.
Licensing 52
52 
Lilly adds to pain pipeline with Asahi Kasei licensing deal
pharmaphorum
JANUARY 29, 2021
US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up to $410 million. The new drug has already cleared phase 1 single and multiple ascending dose and clinical pharmacology studies, according to Lilly.
Licensing 52
52 
IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents
XTalks
JANUARY 22, 2025
Valneva SE, who developed the worlds first FDA-approved chikungunya vaccine , has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus.
Novartis taps immuno-oncology partner BeiGene for TIGIT drug
pharmaphorum
DECEMBER 21, 2021
Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Novartis licensed rights to tislelizumab for $650 million upfront and up to $1.55 billion, providing a partner for its PD-1 agent Opdivo (nivolumab).
Drugs 98
98 
FDA slaps partial hold on Biogen, InnoCare MS drug
pharmaphorum
DECEMBER 28, 2022
Biogen’s efforts to replenish its multiple sclerosis pipeline have suffered a setback, after the FDA placed a clinical hold on a drug candidate it licensed from China’s InnoCare last year for $125 million upfront. InnoCare says it will also introduce the restrictions on studies ongoing outside the US.
Drugs 75
75 
PB-357 by Puma Biotechnology for Breast Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
PB-357 is under clinical development by Puma Biotechnology and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through oral route.
Drugs 100
100 
PB-357 by Puma Biotechnology for Breast Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 10, 2023
PB-357 is under clinical development by Puma Biotechnology and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through oral route.
Drugs 100
100 
ACD-440 by AlzeCure Pharma for Neuropathic Pain (Neuralgia): Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 24, 2023
ACD-440 is under clinical development by AlzeCure Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.
Development 100
100 
Setanaxib by Calliditas Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). GlobalData’s report assesses how Setanaxib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Clinical Trials 100
100 
Regulatory Strategy Considerations for Working with the FDA vs the EMA, Part 1
Camargo
AUGUST 11, 2021
In this two-part blog series, we will explore the regulatory strategy considerations sponsors should bear in mind when working with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with a focus on the development of drug and biologic products. Approval Process: FDA vs EMA Procedures.
Production 230
230 
Poseida and Roche to develop cell therapies for hematologic cancers
Pharmaceutical Technology
AUGUST 4, 2022
P-BCMA-ALLO1 is currently being analysed in a Phase I clinical trial while an investigational new drug (IND) application for P-CD19CD20-ALLO1 is anticipated next year. Furthermore, Roche will oversee the late-stage clinical development and worldwide marketing of all products under the alliance.
Development 147
147 
Orvacabtagene autoleucel by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
Orvacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. Buy the report here.
Pharmacy 100
100 
Sanofi buys US immuno-oncology biotech Amunix for $1 billion
pharmaphorum
DECEMBER 21, 2021
The front-loaded deal also includes $225 million in future payments tied to meeting development milestones, and adds to Sanofi’s current pipeline of around 20 oncology drug candidates. billion deal to buy Kadmon Pharma and its recently-approved drug Rezurock (belumosudil) for chronic graft versus host disease (GVHD).
Licensing 124
124 
Lacerta partners with Prevail to develop AAV capsids for CNS diseases
Pharmaceutical Technology
AUGUST 24, 2022
Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. .
Development 130
130 
MP-0310 by Molecular Partners for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.
Protein 100
100 
MP-0310 by Molecular Partners for Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is administered through intravenous route.
Protein 100
100 
Lilly’s Lepodisiran Achieves Over 90% Reduction in Heart Disease Marker in Phase II Trial
XTalks
APRIL 3, 2025
Safety assessments also indicated that lepodisiran was well-tolerated, with no serious adverse events related to the drug reported. Lilly shared that the ACCLAIM-Lp(a) Phase III clinical development program is currently enrolling. Amgens olpasiran (previously known as AMG 890) is licensed from Arrowhead Pharmaceuticals.
Trials 59
59 
Sanofi wagers $400m on miRecule muscular dystrophy therapy
pharmaphorum
OCTOBER 5, 2022
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”
RNA 105
105 
AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics
pharmaphorum
SEPTEMBER 17, 2020
AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a needle. The post AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics appeared first on.
Drugs 66
66 
Regeneron, CytomX announce bispecific therapeutics for cancer collab
pharmaphorum
NOVEMBER 18, 2022
Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies. Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.
Antibody 105
105 
Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 Juyou Bio-Technology Co.,
Licensing 40
40 
Let's personalize your content